Key result
Gene editing therapy targeting genes like PCSK9, APOC3, ANGPTL3, and IDOL has demonstrated benefits in managing atherosclerosis in animal models.
Why the study?
Gene editing nucleases offer potential cures for human diseases, and studies in animal models have demonstrated advantages of gene editing therapy in atherosclerosis, prompting a review of this therapeutic option for cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Gene editing therapies targeting lipid metabolism genes represent a promising future therapeutic option for cardiovascular diseases.
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) conducted a review in Cardiovascular diseases (atherosclerosis). Gene editing therapy (GETx) was evaluated. Gene editing therapy targeting genes like PCSK9, APOC3, ANGPTL3, and IDOL has demonstrated benefits in managing atherosclerosis in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: